The test, called the A+PSA assay, also reduced the rate of false-positives, tests that indicate the presence of cancer when no disease is actually present, said Gang Zeng, an associate professor of urology, a Jonsson Cancer Center researcher and senior author of the study.
"This is a very promising new approach," Zeng said. "Instead of using just one parameter, PSA, to test for prostate cancer, we use multiple parameters that can be measured in a single reaction."
The study appears in the May issue of the peer-reviewed Journal of Translational Medicine.
The conventional PSA test for prostate cancer has been used for nearly 30 years and is not specific enough in delineating between malignancies and non-malignant diseases of the prostate, such as benign prostatic hyperplasia (BPH), an enlarging of the prostate common in aging men that increases PSA levels, Zeng said.
The retrospective study used blood taken before surgery from 131 patients from UCLA, Japan and France with biopsy-confirmed prostate cancers and compared results to blood taken from 121 men with either BPH or prostatitis, an infection or inflammation of the prostate that increases PSA levels. The study focused on six specific prostate-cancer associated antigens – NY-ESO-1, SSX-2,4, XAGE-lb, AMACR, p90 and LEDGF - which are found predominantly in patients with prostate cancer and not in benign prostate conditions.
The A+PSA assay looked simultaneously for PSA and antibodies to the six prostate-cancer associated antigens in a single reaction test done in a laboratory, much like PSA is measured. The new test takes about two hours, again similar to the PSA test. The test results in an index of numbers used to diagnose cancer, with a score of 0 to 0.5 indicating a benign result and 0.5 to 1 indicating the presence of prostate cancer, Zeng said.
In the new test, sensitivity - the percentage of men with prostate cancer who were correctly identified as having a malignancy - was 79 percent compared to the 52 percent found in PSA testing. Specificity - the percentage of healthy men who were correctly identified as not having prostate cancer - was 84 percent compared to the 79 percent found when testing for PSA alone.
The rate of false-positives using conventional PSA testing is 21 percent. With the new A+PSA assay, the false-positive rate is 16 percent, Zeng said.
"Science has improved so much since the PSA test was developed and I think it's time for a more specific and sensitive test to be developed," Zeng said. "I think we have a test that has great potential to improve the diagnosis of prostate cancer. I knew it would be better than the classic PSA test, but I was amazed at how much better it really was in this study."
Dr. Allan Pantuck, an associate professor of urology, Jonsson Cancer Center researcher and a study author, said a more specific and sensitive test for prostate cancer would be a welcome addition to the diagnostic tool box.
"While measuring PSA is useful in identifying men with prostate cancer, some men with prostate cancer have a normal PSA level and small elevations in PSA above normal may be produced both by prostate cancer as well as an enlarged but benign prostate," Pantuck said. "Combining PSA with a panel of tests that measure an individual man's anti-cancer immune response may better identify who has prostate cancer and who can be spared an unnecessary invasive biopsy."
Zeng and his team are working now to adjust and improve the statistical index used in their test to generate the "score." He'd like to do a prospective study that would include the racial, ethnic and age information for each man who provides blood. The test could perhaps be altered for men over a certain age if the antibody levels found in their blood vary. African-American men may also have varying levels of the six antibodies. There also are additional antibodies that could be added to the assay that may improve both the sensitivity and specificity of the test, Zeng said.
"Different men may have different levels of the six antibodies or different antibodies all together based on their race, age and ethnicity," Zeng said. "We want as accurate an assay as we can possibly develop."
Any new prostate cancer test would have to be approved by the U.S. Food & Drug Administration.
The study was funded in part by the Prevent Cancer Foundation, the National Institutes of Health and the National Cancer Institute Early Detection Research Network.
UCLA's Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2010, the Jonsson Cancer Center was named among the top 10 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 10 of the last 11 years. For more information on the Jonsson Cancer Center, visit our website at http://www.cancer.ucla.edu.
One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center
The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...
19.06.2017 | Event News
13.06.2017 | Event News
13.06.2017 | Event News
23.06.2017 | Physics and Astronomy
23.06.2017 | Physics and Astronomy
23.06.2017 | Information Technology